Literature DB >> 26323289

PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.

Anna Roubtsova1, Ann Chamberland1, Jadwiga Marcinkiewicz1, Rachid Essalmani1, Ali Fazel2, John J Bergeron2, Nabil G Seidah1, Annik Prat1.   

Abstract

Proprotein convertase subtilisin kexin type 9 (PCSK9), the last member of the family of Proprotein Convertases related to Subtilisin and Kexin, regulates LDL-cholesterol by promoting the endosomal/lysosomal degradation of the LDL receptor (LDLR). Herein, we show that the LDLR cell surface levels dramatically increase in the liver and pancreatic islets of PCSK9 KO male but not female mice. In contrast, in KO female mice, the LDLR is more abundant at the cell surface enterocytes, as is the VLDL receptor (VLDLR) at the cell surface of adipocytes. Ovariectomy of KO female mice led to a typical KO male pattern, whereas 17β-estradiol (E2) treatment restored the female pattern without concomitant changes in LDLR adaptor protein 1 (also known as ARH), disabled-2, or inducible degrader of the LDLR expression levels. We also show that this E2-mediated regulation, which is observed only in the absence of PCSK9, is abolished upon feeding the mice a high-cholesterol diet. The latter dramatically represses PCSK9 expression and leads to high surface levels of the LDLR in the hepatocytes of all sexes and genotypes. In conclusion, the absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR and VLDLR, which is determined by E2 levels.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cholesterol; estrogen; ldl/metabolism; lipoproteins/receptors; liver

Mesh:

Substances:

Year:  2015        PMID: 26323289      PMCID: PMC4617400          DOI: 10.1194/jlr.M061952

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  45 in total

1.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

2.  Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Authors:  Chutikarn Butkinaree; Maryssa Canuel; Rachid Essalmani; Steve Poirier; Suzanne Benjannet; Marie-Claude Asselin; Anna Roubtsova; Josée Hamelin; Jadwiga Marcinkiewicz; Ann Chamberland; Johann Guillemot; Gaétan Mayer; Sangram S Sisodia; Yves Jacob; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

3.  Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.

Authors:  Ilaria Guella; Rosanna Asselta; Diego Ardissino; Pier Angelica Merlini; Flora Peyvandi; Sekar Kathiresan; Pier Mannuccio Mannucci; Marco Tubaro; Stefano Duga
Journal:  J Lipid Res       Date:  2010-08-10       Impact factor: 5.922

4.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

5.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

6.  Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoprotein-receptor.

Authors:  Jens C Brüning; Philipp Lingohr; Jennifer Gillette; Bettina Hanstein; Haluk Avci; Wilhelm Krone; Dirk Müller-Wieland; Jörg Kotzka
Journal:  J Steroid Biochem Mol Biol       Date:  2003-08       Impact factor: 4.292

7.  The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner.

Authors:  G Cerillo; A Rees; N Manchanda; C Reilly; I Brogan; A White; M Needham
Journal:  J Steroid Biochem Mol Biol       Date:  1998-10       Impact factor: 4.292

8.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype.

Authors:  Jonna Frasor; Jeanne M Danes; Barry Komm; Ken C N Chang; C Richard Lyttle; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2003-07-10       Impact factor: 4.736

9.  Molecular basis for LDL receptor recognition by PCSK9.

Authors:  Hyock Joo Kwon; Thomas A Lagace; Markey C McNutt; Jay D Horton; Johann Deisenhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

10.  LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.

Authors:  Noam Zelcer; Cynthia Hong; Rima Boyadjian; Peter Tontonoz
Journal:  Science       Date:  2009-06-11       Impact factor: 47.728

View more
  20 in total

1.  Kalirin/Trio Rho GDP/GTP exchange factors regulate proinsulin and insulin secretion.

Authors:  Quinn Dufurrena; Nils Bäck; Richard E Mains; Louis Hodgson; Herbert Tanowitz; Prashant Mandela; Elizabeth Eipper; Regina Kuliawat
Journal:  J Mol Endocrinol       Date:  2018-11-01       Impact factor: 5.098

2.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

3.  Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Authors:  Amy E Levenson; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; R Paul Wadwa; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2017-01-17       Impact factor: 4.866

4.  Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.

Authors:  Paul Lebeau; Ali Al-Hashimi; Sudesh Sood; Šárka Lhoták; Pei Yu; Gabriel Gyulay; Guillaume Paré; S R Wayne Chen; Bernardo Trigatti; Annik Prat; Nabil G Seidah; Richard C Austin
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

5.  The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.

Authors:  Delia Susan-Resiga; Emmanuelle Girard; Robert Scott Kiss; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Zuhier Awan; Chutikarn Butkinaree; Alexandre Fleury; Armand Soldera; Yves L Dory; Alexis Baass; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

Review 6.  Dynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise training.

Authors:  Jean-Marc Lavoie
Journal:  World J Hepatol       Date:  2016-08-18

7.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.

Authors:  Elodie Weider; Delia Susan-Resiga; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Surendra Nimesh; Yahya Ashraf; Keith L Wycoff; Jianbing Zhang; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-06-08       Impact factor: 5.157

8.  Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.

Authors:  Amy E Levenson; Mary E Haas; Ji Miao; Rebecca J Brown; Sarah D de Ferranti; Ranganath Muniyappa; Sudha B Biddinger
Journal:  Endocrinology       Date:  2016-01-29       Impact factor: 4.736

Review 9.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

Review 10.  Mouse Models of Human Proprotein Convertase Insufficiency.

Authors:  Manita Shakya; Iris Lindberg
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.